A Review on Elemental Impurity Control under ICH Q3D

Abstract

The presence of elemental impurities (EIs) in pharmaceuticals arising from catalysts, environmental contaminants, or manufacturing equipment poses a significant risk to patient safety due to potential systemic toxicity and lack of therapeutic benefit.  This review evaluates the implementation of the ICH Q3D guideline, which transitioned the industry from non-specific "heavy metals" tests to a rigorous, science-based toxicological framework.  The article details the classification of 24 elements, the calculation of Permitted Daily Exposure (PDE) across different administration routes, and the requirement for multi-disciplinary risk assessments. It further examines the technical superiority of Inductively Coupled Plasma (ICP) technologies over legacy methods. ICH Q3D represents a pivotal shift in pharmaceutical quality assurance, emphasizing proactive risk management and high-sensitivity analytical validation to ensure global regulatory alignment and patient protection.